ProCE Banner Activity

STAMPEDE Combined Analysis of ADT Plus Abiraterone Acetate + Prednisolone ± Enzalutamide vs ADT Alone in High-Risk Nonmetastatic Prostate Cancer

Slideset Download
Conference Coverage
In this combined analysis from the ongoing STAMPEDE platform trial, 2 years of abiraterone acetate plus prednisolone added to ADT was associated with a significant improvement in metastasis-free survival and OS in patients with high-risk nonmetastatic prostate cancer.

Released: September 30, 2021

Expiration: September 29, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc